Hua Medicine

Hua Medicine is a leading China-based biotechnology company focused on developing first-in-class therapies for patients with unmet medical needs in metabolic and neurodegenerative diseases. The company is best known for developing dorzagliatin (HuaTangNing), a first-in-class glucokinase activator (GKA) that received marketing approval in China in 2022 for the treatment of Type 2 Diabetes Mellitus. Hua Medicine's unique approach focuses on restoring glucose homeostasis by repairing the glucose-sensing function of glucokinase in the pancreas, liver, and gut. The company has established a major strategic partnership with Bayer for the commercialization of dorzagliatin in China while continuing to advance a pipeline of combination therapies and new indications. Hua Medicine is listed on the Hong Kong Stock Exchange and continues to explore the potential of GKAs in chronic kidney disease and other metabolic conditions.